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N-alkylamides 
- Plant secondary metabolites 
- Occurrence > 25 plant families 
- Wide structural diversity 
 
- Various functionalities i.e. antimicrobial, insecticidal, sensory,  
   anti-inflammatory, immune-modulating,   
   central nervous system effects (CNS):  
 * analgesic, anticonvulsant, antidepressant, anti-oxidant, anti-    
    inflammatory activity 
 * protection against neurodegeneration  
 * cognitive enhancing effects  
 
- 2 model N-alkylamides (NAAs): spilanthol (logP 3.39) and pellitorine (logP 3.65) 
 
 
 
 
 
 
  
Spilanthol 
deca-2E,6Z,8E-trienoic acid isobutylamide 
(present in Spilanthes acmella) 
 
Pellitorine  
deca-2E,4E-dienoic acid isobutylamide 
(present in Anacyclus pyrethrum) 
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N-alkylamides (spilanthol and pellitorine) enter the systemic 
blood circulation after different routes of administration: 
 
- Oral:  
 *In vitro Caco-2 cell monolayer experiment1 
 *In vivo oral gavage experiment with rats1 
 penetrate the intestinal barrier 
 
 
-Topical:  
 *In vitro transdermal Franz diffusion cell experiment using human 
   skin and pig mucosa2-4 
 penetrate the stratum corneum  
 
 
 
 
 
 
 
 
  
1: Veryser et al. (2015). Gut and blood-brain barrier pharmacokinetics of the plant N-alkylamide spilanthol using in vitro and in vivo rodent  
 models. Manuscript in preparation.   
2: Boonen et al. (2010). LC-MS profiling of N-alkylamides in Spilanthes acmella extract and the transmucosal behaviour of its main bio-active  
 spilanthol. J. Pharm. Biomed. Anal. 53(3), 243-249.  
3: Boonen et al. (2010). Transdermal behaviour of the N-alkylamide spilanthol (affinin) from Spilanthes acmella (Compositae) extracts.  
 J. Ethnopharmacol. 127, 77-84. 
4: Veryser et al. (2014). Quantitative transdermal behavior of pellitorine from Anacyclus pyrethrum. Phytomedicine. 21(14), 1801-1807. 
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NAAs in blood  brain ??? 
 
To investigate the permeability of spilanthol and pellitorine through  
blood-brain barrier (BBB)  
 
 1. Influx: from blood-to-brain 
 
  a) Multiple time regression (MTR) experiment
  b) Capillary depletion experiment (brain distribution)
  
 2. Efflux: from brain-to-blood 
 
  
  
Investigation using the gold-standard  
               in vivo method  
 
 
 
 
 
 
 
 
  
NAA NAA 
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In vivo blood-brain barrier (BBB) experiment with mice  
1. Influx (blood-to-brain transport)  
 - Dose= spilanthol: 2.77 mg/kg mouse, pellitorine: 1.23 mg/kg mouse 
 - IV injection 
 
 a) Multiple time regression (MTR) experiment 
 - Collection of serum and isolation of brain at specified time points 
 
 b) Capillary depletion (brain distribution) experiment 
 - Collection of serum and isolation of brain after 10 min. 
   
 
2. Efflux (brain-to-blood transport) 
 - Dose= spilanthol: 0.14 mg/kg mouse, pellitorine: 0.06 mg/kg mouse 
 - Intraventricular injection  
 - Collection of serum and isolation of brain at specified time points 
  
Samples analysed using a bio-analytical UPLC-MS method   
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Kinetic parameters of spilanthol 
t1/2,elimination = 3.16 min  
kelimination = 0.22 min
-1  
C0 = 3.05 µg/ml 
 
Kinetic parameters of pellitorine 
t1/2,elimination (b) = 4.48 min  
a = 1.56 min-1  
b = 0.15 min-1  
C1 = 7.02 µg/ml 
C2 = 0.44 µg/ml 
 
 
 
1. Influx: blood-to-brain 
 a) MTR results  
 Serum profiles 
   
          Spilanthol                    Pellitorine 
       one-compartmental model              two-compartmental model 
 
 
 
 
 
 
  
C = C0 × e
−ke×t Cp = C1 × e
−α×t  + C2 × e
−β×t 
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 Brain/serum concentration profiles: biphasic model  
 
             Spilanthol 
 
 
 
 
 
 
 
  
            (If V0 and K>0: Vg = 344 µl/g; K1 = 217 µl/g·min) 
 
 
    (If V0 and K>0: Vg = 807 µl/g; K1 = 159 µl/g·min) 
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Pellitorine 
 
K1 = 153 µl/g·min 
Vg = 792 µl/g  
 
 
 
K1 = 796 µl/g·min 
Vg = 652 µl/g 
 
 
Am(t) = the concentration of NAA in the brain at time t (ng/g)  
Cp(t) = the concentration of NAA in serum at time t (ng/µl) 
K1 = unidirectional clearance (µl/(g·min)) 
K = the net clearance (µl/(g·min)): 10-16 ~ 0 
Vg = tissue brain distribution volume (µl/g) 
V0 = vascular brain distribution volume (µl/g): 14.8 (BSA) 
Θ = exposure time: x-axis 
y-axis 
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 b) Capillary depletion: brain distribution  
   
               Spilanthol          Pellitorine 
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2. Efflux: brain-to-blood 
   
         Spilanthol      Pellitorine 
  
 
 
 
 
 
 
  
Kinetic parameters of spilanthol 
kout = 0.11 min
-1 
t1/2,brain = 6.38 min 
 
Kinetic parameters of pellitorine 
kout = 0.05 min
-1 
t1/2,brain = 13.78 min 
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Conclusions 
 
- Spilanthol and pellitorine are able to pass the BBB 
 
- Both NAAs show a rapid and high influx rate, with pellitorine somewhat 
 
  higher BBB influx permeation compared to spilanthol   
 
- Similar Kin values were obtained compared to CNS small molecules 
 
- > 95% of NAAs was found in parenchyma of the brains, < 5% in the  capillaries            
 possibility to exert CNS effects  
 
- There is also efflux from the brain into the blood 
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